Provention Bio, in need of AdComm's support for diabetes drug, may have what it needs...

[cafead]

via Provention Bio’s stock flew skyward Tuesday as FDA advisory panel documents apparently backed the efficacy of its diabetes prevention drug teplizumab while avoiding a larger question about the quality of the biotech's manufacturing.

article source